People have the right to be involved in discussions and make informed decisions about their care, as described in NICE's information on making decisions about your care. Making decisions using NICE ...

Just over 4,200 people could be set to benefit after Sparsentan (also known as Filspari and made by Vifor Pharma) was recommended in final draft guidance as an option for treating primary ...

Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency TA1064 22 May 2025 22 May ...

Comparator companies Ipsen (somatropin) (confidentiality agreement not signed, not participating) Lilly (somatropin) (confidentiality agreement not signed, not participating) Merck Serono (somatropin) ...

Given as a once-weekly injection under the skin using a pre-filled syringe or pen, marstacimab is also the first haemophilia B treatment that works by targeting a protein in the blood clotting process ...

NICE is unable to make a recommendation on baloxavir marboxil (Xofluza) for treating acute uncomplicated influenza in people aged 12 and over. This is because Roche did not provide an evidence ...

The treatment, called relugolix–estradiol–norethisterone (also known as relugolix combination therapy or Ryeqo), works by blocking specific hormones that contribute to endometriosis, while also ...

This guideline has been updated and replaced by NICE guideline NG245. Back to top ...

This guideline covers the prevention and management of overweight, obesity and central adiposity in children, young people and adults. It brings together and updates all NICE's previous guidelines on ...

Our mission is to get the best treatment and care to patients fast at value to the taxpayer. Through this forward view, we will highlight the topics we are focusing on, and that matter most to you in ...

Risk factors for progression to severe COVID‑19 in adults defined by the independent advisory group commissioned by the Department of Health and Social Care (June 2023) ...